Argenica Therapeutics Ltd (AU:AGN) has released an update.
Argenica Therapeutics has enhanced its board with the addition of Dr. Mark Etherton and Mr. Rob Black, bringing in a wealth of expertise in neurology drug development and financial markets. The appointments are set to bolster Argenica’s transition into a pharmaceutical development company, focusing on novel therapeutics for brain injuries and neurodegenerative diseases. The company is actively pursuing clinical trials for its lead neuroprotective peptide candidate, ARG-007, aimed at improving outcomes for stroke and other brain injury patients.
For further insights into AU:AGN stock, check out TipRanks’ Stock Analysis page.